Pin Therapeutics announced on Monday that it delivered an oral presentation on its TPD platform technology, “PinMARS,” at the 8th Annual TPD & Induced Proximity Summit held in Boston, Mass., and pursued joint R&D discussions with global pharmaceutical and biotech companies.
The TPD Summit is the world's largest conference on targeted protein degradation (TPD), and Pin Therapeutics has actively engaged with the industry by presenting major research achievements at the conference each year.
At this year's event, Pin Therapeutics CEO Jo Hyun-sun spoke during the New E3 Ligase Session on Day 4, revealing the latest research data and strategic vision for the PinMARS platform based on the novel E3 ligase Ligase 2.
In his presentation, CEO Jo highlighted the broad potential for pipeline expansion.
He discussed progress in developing Pan-KRAS degraders with Ligase 2, a new strategy for targeted degradation of membrane proteins, and potential applications for CNS diseases. This approach could overcome the limits of TKI and antibody therapies.
Ligase 2 is considered a novel E3 ligase that may dramatically reduce blood and immune toxicity compared to CRBN/VHL, which is widely used in the industry. Ligase 2 shows minimal expression and low degradation activity in normal blood and immune cells.
The company said that after the announcement, joint R&D discussions for Ligase 2-based TPD started immediately on-site with several multinational pharmaceutical companies. Follow-up meetings are ongoing.
Notably, Pin Therapeutics has recently accelerated the construction of a molecular-glue-like library using Ligase 2 and is discussing joint research partnerships with global biotech companies in this field. The company plans to expand the Ligase 2-based TPD ecosystem and secure a unique position in next-generation MGD/molecular-glue technology.
The PinMARS platform is a next-generation TPD engine. It integrates Pin Therapeutics’ proprietary E3 ligase screening technology, binding-affinity and activity-analysis methods, and molecular-optimization technology.
The platform is built around the novel E3 Ligase 2 instead of the more common CRBN/VHL. This gives Pin Therapeutics exclusive development rights and a chance to expand into diverse indications. The company aims to strengthen its global position by building a portfolio that includes Pan-KRAS degraders, antibody-degrader-conjugate payloads, and CNS TPD projects.
“This year's TPD Summit showed global industry interest in the Ligase 2 platform,” a Pin Therapeutics official said. “Discussions are moving forward with our partners for joint research and molecular-glue development using Ligase 2, currently the most rapidly advancing topic. We will lead the development of next-generation E3-ligase-based TPDs.”